Background and objectivesUnani medicine is gaining popularity as primary or adjunct therapy in the treatment of type-2 diabetes; however, no published data on the prevalence of its use, usage pattern and perceived benefits in diabetes patients are available. Therefore, the present study was aimed to estimate the prevalence, pattern of use and perceived benefits of Unani medicines for diabetics. Materials and methodsA hospital-based cross-sectional study on 484 type-2 diabetes patients was conducted from January to December 2018 at an urban primary health centre in Bengaluru, India. Systematic random sampling method was used to obtain the required sample size. Information from patients was gathered through personal interview using a semi-structured questionnaire after obtaining their written informed consent. A treatment satisfaction questionnaire for medication (version 1.4) was used to assess the major dimensions of patient’s satisfaction with treatment. ResultsUnani medicine use was found in 25.6 % of diabetics. Qurs ziabetes was the most used Unani drug, with majority of users taking four tablets three times a day. Most of the patients had been using Unani medicines for 1 year. Usage of Unani medicines improved all aspects of patient satisfaction including effectiveness, safety, and overall satisfaction in comparison to non-users (p = 0.001). Glycemic control was found to be better in Unani medicine users than non-users (P < 0.05). ConclusionThe finding of the study leads us to conclude that a considerable proportion of diabetics utilize Unani medicines together with conventional treatment and that their use was found to be effective and safe in controlling blood sugar levels.